Sort
10,766 grants matching “checkpoint inhibitor”
Targeting Sox10-low cells in drug-resistant melanoma
$44,524Sean Alexander Misek · Michigan State University · F31 · FY2018 · CA
Role of ER stress-driven IRE1α-XBP1 Signaling in Lung Cancer Pathogenesis
$44,524Michael Joseph Crowley · Weill Medical Coll Of Cornell Univ · F31 · FY2018 · CA
Regulation of transendothelial migration of Tregs in irradiated HNSCCs by EphB4-ephrinB2 interaction
$44,494Laurel B Darragh · University Of Colorado Denver · F31 · FY2023 · DE
The role of PTEN in DNA metabolism and replication
$44,436Abigail Rose Lubin · Icahn School Of Medicine At Mount Sinai · F31 · FY2021 · CA
Immunomodulatory Nanoparticles in Combination with Immune Checkpoint Inhibitors for the Systemic Treatment of Immunosuppressive HPV Associated Oropharyngeal Cancer
$44,376Jared Michael Newton · Baylor College Of Medicine · F31 · FY2016 · DE
Investigating the Role of DNA Repair Mutations in Prostate Cancer Initiation, Progression, and Susceptibility to Targeted Therapies
$44,369Sander Barkley Frank · Fred Hutchinson Cancer Research Center · F32 · FY2021 · CA
Balancing Efficacy and Toxicity of Intratumoral Reolysin for Diffuse Intrinsic Pontine Glioma (DIPG)
$44,244Matthew Schuelke · Mayo Clinic Rochester · F30 · FY2017 · CA
Improving Efficacy and Safety of VSV Immunotherapy for Metastatic Melanoma
$44,244Kevin G Shim · Mayo Clinic Rochester · F30 · FY2017 · CA
Immunoediting in Human Cancer
$44,237Ron S Gejman · Weill Medical Coll Of Cornell Univ · F30 · FY2016 · CA
Dissecting the interactions between TCR signaling strength and inhibitory pathways
$44,118Lin Shen · University Of California, San Francisco · K08 · FY2023 · AI
Role of ER stress-driven IRE1α-XBP1 Signaling in Lung Cancer Pathogenesis
$44,044Michael Joseph Crowley · Weill Medical Coll Of Cornell Univ · F31 · FY2017 · CA
Genotoxic effects of L1 retrotransposition trigger oocyte elimination during MPI
$44,044Marla Elizabeth Tharp · Johns Hopkins University · F31 · FY2017 · HD
Biomimetic artificial antigen presenting cells for melanoma immunotherapy
$44,044Randall A Meyer · Johns Hopkins University · F31 · FY2017 · CA
Cleavage of Bcl-xL by Caspases contributes to cell death in vivo
$44,044Jason Huska · Johns Hopkins University · F31 · FY2017 · AI
Chemical Biology of BubR1
$43,996Joel Stuart Sandler · Rockefeller University · F32 · FY2006 · GM
Program 4: Leukemia
$43,922Benjamin Levine Ebert · Dana-Farber Cancer Inst · P30 · FY2017 · CA
The role of PTEN in DNA metabolism and replication
$43,920Abigail Rose Lubin · Icahn School Of Medicine At Mount Sinai · F31 · FY2020 · CA
Lymphoma & Leukemia Research Program (Project-007)
$43,896Ronald Levy · Stanford University · P30 · FY2018 · CA
Lymphoma & Leukemia Research Program (Project-007)
$43,892Ronald Levy · Stanford University · P30 · FY2020 · CA
Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer
$43,878John Nathaniel Diehl · Univ Of North Carolina Chapel Hill · F30 · FY2020 · CA
Immunoediting in Cutaneous Squamous Cell Carcinoma
$43,877Elizabeth Borden · University Of Arizona · F30 · FY2024 · CA
Immunoediting in Human Cancer
$43,781Ron S Gejman · Weill Medical Coll Of Cornell Univ · F30 · FY2015 · CA
Improving Efficacy and Safety of VSV Immunotherapy for Metastatic Melanoma
$43,776Kevin G Shim · Mayo Clinic Rochester · F30 · FY2016 · CA
Lymphoma & Leukemia Research Program (Project-007)
$43,761Ronald Levy · Stanford University · P30 · FY2019 · CA
PTPN1 and PTPN2 as targets to improve NK function against HIV
$43,756Claudia Melo · George Washington University · F31 · FY2024 · AI